Miluna Acquisition Corp filed its quarterly report on Form 10-Q for the period ended September 30, 2026, with the SEC on November 9, 2026, disclosing financial results and balance sheet data for the blank-check company listed on NASDAQ:MMTX.
W. R. Berkley Corporation and its subsidiary Berkley Insurance Company filed Amendment No. 3 to Schedule 13G on November 9, 2026, disclosing beneficial ownership of Class A ordinary shares in Kochav Defense Acquisition Corp. as of September 30, 2026.
Select Water Solutions, Inc. filed its quarterly report on Form 10-Q with the Securities and Exchange Commission for the period ended September 30, 2026, disclosing share counts and key company details as of November 5, 2026.
Kochav Defense Acquisition Corp. filed a Form 8-K on November 9, 2026, disclosing updated trust account contribution terms ahead of its extraordinary general meeting scheduled for November 13, 2026.
Abeona Therapeutics Inc. filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission on November 9, 2026, covering the fiscal quarter ended September 30, 2026.
Kochav Defense Acquisition Corp. filed a quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission on November 9, 2026, covering the period ended September 30, 2026.
Xenon Pharmaceuticals Inc. filed a Form S-8 registration statement with the U.S. Securities and Exchange Commission on November 9, 2026, registering an additional 300,000 common shares under its Amended and Restated 2025 Inducement Equity Incentive Plan.
Tecnoglass Holdings Inc. filed a Form 8-K/A (Amendment No. 1) on November 9, 2026, correcting its previously reported third-quarter and nine-month 2026 financial results to reflect a valuation allowance on a deferred tax asset related to treasury stock accounting.
Tecnoglass Holdings Inc. (NYSE:TGLS) filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 9, 2026, reporting total operating revenues of $310.6 million for the third quarter and net income of $16.7 million.
Xenon Pharmaceuticals Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026, with the SEC on November 9, 2026, disclosing balance sheet data showing total assets of $1,199,875 thousand and an accumulated deficit of $1,568,853 thousand.